{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:12:12Z","timestamp":1793193132522,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000135","name":"National Institutes of Health Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["R01AG073212"],"award-info":[{"award-number":["R01AG073212"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000135","name":"National Institutes of Health Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["R01AG059008"],"award-info":[{"award-number":["R01AG059008"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG072980"],"award-info":[{"award-number":["P30 AG072980"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009797","name":"Barrow Neurological Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["GC-2013717"],"award-info":[{"award-number":["GC-2013717"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.medj.2025.100771","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:41:50Z","timestamp":1754664110000},"page":"100771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Alzheimer\u2019s disease: Clinical trials to watch"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-3309","authenticated-orcid":false,"given":"Marwan Noel","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Decourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100771_bib1","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.medj.2025.100771_bib2","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.medj.2025.100771_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","article-title":"Pyroglutamate Abeta cascade as drug target in Alzheimer's disease","volume":"27","author":"Bayer","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.medj.2025.100771_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14712598.2025.2463963","article-title":"Successes and failures: the latest advances in the clinical development of amyloid-beta-targeting monoclonal antibodies for treating Alzheimer's disease","volume":"25","author":"Panza","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.medj.2025.100771_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.medj.2025.100771_bib6","unstructured":"Alz Forum Press Release (2025). AD\/PD 2025: Advances in Science & Therapy. https:\/\/www.alzforum.org\/print-series\/3423841."},{"key":"10.1016\/j.medj.2025.100771_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14283\/jpad.2022.93","article-title":"ACU193, a Monoclonal Antibody that Selectively Binds Soluble Ass Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan","volume":"10","author":"Siemers","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2025.100771_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100082","article-title":"Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease","volume":"12","author":"Cline","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2025.100771_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","article-title":"Effects of Oral ALZ-801\/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.medj.2025.100771_bib10","unstructured":"Alzheon Press Release (2025). Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate\/ALZ-801 in Patients with Early Alzheimer\u2019s Disease Carrying Two Copies of APOE4 Gene. https:\/\/alzheon.com\/topline-results-from-pivotal-apolloe4-phase-3-trial-of-oral-valiltramiprosate-alz-801-in-patients-with-early-alzheimers-disease-carrying-two-copies-of-apoe4-gene\/."},{"key":"10.1016\/j.medj.2025.100771_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2025.100771_bib12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2025.100771_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/15548627.2019.1586248","article-title":"SIGMAR1\/Sigma-1 receptor ablation impairs autophagosome clearance","volume":"15","author":"Yang","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.medj.2025.100771_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100016","article-title":"Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB\/III trial","volume":"12","author":"Macfarlane","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2025.100771_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases","volume":"127","author":"Nguyen","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.medj.2025.100771_bib16","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimer's Dement."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T22:41:13Z","timestamp":1756248073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666634025001989"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100771","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer\u2019s disease: Clinical trials to watch","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100771"}}